Company Overview

RxSight, Inc. is a commercial-stage medical technology company focused on improving outcomes in cataract surgery through adjustable intraocular lens technology. The company operates within the ophthalmology and medical devices industries, specifically addressing refractive accuracy challenges following cataract procedures. Its core innovation is a system that allows physicians to non-invasively adjust a patient’s implanted lens after surgery to optimize visual acuity.

RxSight’s primary revenue drivers are its proprietary Light Adjustable Lens (LAL) and the associated Light Delivery Device (LDD), which together form an integrated platform. The company serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, primarily in developed healthcare markets. Its unique positioning lies in being the first and only company to commercialize an FDA-approved adjustable intraocular lens, offering a differentiated solution compared to traditional fixed-power lenses.

The company was founded in 1997 and spent more than two decades in research, clinical development, and regulatory approval processes before achieving U.S. Food and Drug Administration approval for its core technology. RxSight transitioned to a commercial-stage company following FDA approval and completed its initial public offering in 2021, marking its evolution from a development-focused enterprise to a revenue-generating medical device manufacturer.

Business Operations

RxSight operates as a single-segment company focused on the development, manufacturing, and commercialization of its adjustable lens platform. Revenue is generated through sales of the Light Adjustable Lens, the Light Delivery Device, and recurring revenue from consumables and post-operative adjustment procedures tied to lens usage. The business model combines capital equipment sales with per-procedure and per-lens revenue, creating an ongoing revenue stream from installed systems.

Operations include in-house product development, quality-controlled manufacturing, and a direct sales organization primarily targeting ophthalmology providers. While the majority of revenue is generated in the United States, the company also supports select international markets through regulatory approvals and distribution arrangements. RxSight maintains intellectual property related to photosensitive lens materials and light-based adjustment technology as a core operational asset.

Strategic Position & Investments

RxSight’s strategic direction centers on expanding adoption of its adjustable lens technology by increasing surgeon awareness, expanding its installed base of Light Delivery Devices, and driving procedural utilization. Growth initiatives include continued penetration of the U.S. premium cataract market and selective international expansion as regulatory approvals are obtained in additional countries.

The company has invested primarily in internal research and development rather than large-scale acquisitions, focusing on incremental improvements to its existing platform and next-generation lens technologies. RxSight does not operate a diversified portfolio of subsidiaries; instead, it concentrates resources on enhancing clinical outcomes, workflow efficiency, and product scalability within ophthalmology. Emerging areas of focus include broadening indications and improving patient throughput for its light-adjustment process.

Geographic Footprint

RxSight is headquartered in North America, with its principal executive offices located in California, United States. The United States represents its largest and most established market, accounting for the majority of system installations and revenue.

Internationally, the company has expanded into select markets in Europe, Asia-Pacific, and Latin America, subject to local regulatory approvals. Its global footprint remains measured and strategic, with international operations primarily focused on commercial partnerships, distributor relationships, and regulatory market entry rather than large-scale manufacturing outside the U.S.

Leadership & Governance

RxSight is led by a management team with experience in medical devices, ophthalmology, and healthcare commercialization. The leadership emphasizes clinical evidence, disciplined commercialization, and long-term value creation through differentiated technology. Corporate governance follows public company standards, with oversight provided by an independent board of directors.

Key executives include:

• Ron Kurtz – Chief Executive Officer
• Shelly L. Mason – Chief Financial Officer
• Dr. Robert J. Grubbs – Chief Medical Officer
• Douglas E. Lynam – Chief Operating Officer
• Mike D. Wolf – Chief Commercial Officer

The executive team’s strategic vision centers on establishing adjustable lens technology as a new standard of care in cataract surgery while maintaining regulatory compliance, product quality, and sustainable growth.